A wave of investment from large pharmaceutical companies into life sciences startups via mergers and acquisitions could result in a flood of demand in the lab real estate market for the next 18 months. During the first half of this year, a series of multibillion-dollar deals — Pfizer’s $43B acquisition of Seagen, a biotech focused on “revolutionizing cancer care,” Merck’s $11B acquisition of Prometheus Biosciences, and Astellas Pharma’s $5.9B pickup of Iveric Bio — has already pushed total deal volume past last year’s pace.
Travis McCready, head of Life Sciences, Industries Americas for JLL, said there will be between $275B and $300B total in biotech M&A in 2023.A significant chunk of that total deal value will be upfront capital for… Read the full story here. |